Key facts
- This page summarizes Venrock Healthcare Capital Partners II, L.P.'s Form 4 filing for VistaGen Therapeutics, Inc. (VTGN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 14 Jul 2022, 17:33.
Venrock Healthcare Capital Partners II, L.P. - 12 Jul 2022 Form 4 Insider Report for VistaGen Therapeutics, Inc. (VTGN)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- VTGN
- Reported as of
- 12 Jul 2022
- Net transaction value
- -$53,400
- SEC form
- 4
- Accepted by SEC
- 14 Jul 2022, 17:33:58 UTC
- Prior SEC filing
- 06 Jul 2022
- Next SEC filing
- 20 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ David L. Stepp, Authorized Signatory
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Venrock Healthcare Capital Partners II, L.P. filed Form 4 for VistaGen Therapeutics, Inc. (VTGN) on 14 Jul 2022.
Change
- Previous filing in this sequence was filed on 06 Jul 2022.
- Current net transaction value: -$53,400.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VTGN
transaction
Common Stock
Sale
- Transaction value
- $53,400
- Shares
- -60,000
- Change %
- -0.29%
- Price
- $0.8900*
- Shares after
- 20,637,286
- Date
- 12 Jul 2022
- Ownership
- By Funds
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Venrock Healthcare Capital Partners II, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
Consists of 14,348 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), 5,814 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP II Co"), 4,688 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), 469 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP III Co") and 34,681 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.86 to $0.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F3
Consists of 4,935,020 shares held by VHCP II, 1,999,971 shares held by VHCP II Co, 1,612,582 shares held by VHCP III, 161,351 shares held by VHCP III Co and 11,928,362 shares held by VHCP EG.
Footnote F4
VHCP Management II, LLC ("VHCPM II") is the sole general partner of VHCP II and the sole manager of VHCP II Co. VHCP Management III, LLC ("VHCPM III") is the sole general partner of VHCP III and the sole manager of VHCP III Co. VHCP Management EG, LLC ("VHCPM EG") is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM II, VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM II, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP II, VHCP II Co, VHCP III, VHCP III Co and VHCP EG, except to the extent of their respective indirect pecuniary interests therein.